The use of tranexamic acid (TXA) has markedly increased since the results of the CRASH-II trial were published. In addition to its use in trauma, TXA has been evaluated and used in numerous other conditions, including post-partum hemorrhage and epistaxis. Recently, the HALT-IT Trial was published online in the Lancet, which evaluated the use of TXA in patients with acute gastrointestinal bleeding. In this podcast we discuss the HALT-IT Trial and its implications for clinical practice.
You can get CME credit for this episode here!Click here for CME Account Creation Instructions
IVF administration is central to the management of patients with sepsis. Though the Surviving Sepsis Campaign recently downgraded its recommendation on the amount of...
Amniotic fluid embolism (AFE) is a catastrophic syndrome that occurs very soon after delivery and is a significant cause of morbidity and mortality. Unfortunately,...
The use of steroids in patients with sepsis and septic shock has been controversial for decades. At present, the Surviving Sepsis Campaign recommends the...
